PVLA
Palvella Therapeutics, Inc. NASDAQ Listed Jan 2, 2015$155.96
+0.57%
vs $155.07
Mkt Cap $2.2B
52w Low $41.71
95.5% of range
52w High $161.38
50d MA $135.54
200d MA $112.64
P/E (TTM)
—
EV/EBITDA
—
P/B
62.7x
Debt/Equity
0.0x
ROE
-149.1%
P/FCF
-69.8x
RSI (14)
60.60
ATR (14)
$8.12
Beta
-0.20
50d MA
$135.54
200d MA
$112.64
Avg Volume
215.1K
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.
125 Strafford Avenue · Wayne, PA 19087 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 4, 2026 | BMO | -1.17 | -1.52 | -29.9% | 140.78 | -3.9% | +8.0% | +1.9% | +0.0% | +1.8% | -3.5% | — |
| May 7, 2026 | BMO | -0.90 | -1.20 | -33.3% | 130.17 | -0.9% | -13.0% | +7.1% | +0.7% | +3.0% | -4.1% | — |
| Mar 31, 2026 | BMO | -0.91 | -1.08 | -18.5% | 124.65 | +1.0% | -3.4% | +2.6% | -2.9% | +0.1% | +2.6% | — |
| Nov 11, 2025 | BMO | -0.85 | -1.03 | -21.2% | 77.85 | +1.2% | +4.7% | -1.3% | +4.0% | -2.5% | +1.6% | — |
| Aug 14, 2025 | BMO | -0.78 | -0.86 | -10.3% | 46.10 | +2.2% | +2.6% | +4.8% | -2.1% | +4.0% | +1.7% | — |
| May 15, 2025 | BMO | -3.40 | -0.74 | +78.2% | 21.61 | +0.9% | +2.0% | +2.3% | +3.0% | -1.0% | -3.9% | — |
| Mar 31, 2025 | BMO | -0.39 | 4.00 | +1125.6% | 27.99 | +1.1% | -15.7% | +14.3% | -9.4% | -1.8% | -16.3% | — |
| Nov 13, 2024 | BMO | -0.55 | -2.19 | -301.8% | — | — | — | — | — | — | — | — |
| Aug 14, 2024 | BMO | -2.40 | -2.76 | -15.0% | — | — | — | — | — | — | — | — |
| May 16, 2024 | BMO | -4.80 | -2.00 | +58.3% | — | — | — | — | — | — | — | — |
| Mar 30, 2024 | BMO | -9.60 | -3.71 | +61.4% | — | — | — | — | — | — | — | — |
| Nov 15, 2023 | BMO | -8.80 | -8.70 | +1.1% | — | — | — | — | — | — | — | — |
| Aug 11, 2023 | AMC | -12.54 | 3.62 | +128.9% | — | — | — | — | — | — | — | — |
| May 11, 2023 | AMC | -14.68 | -1.17 | +92.0% | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 12 | Stephens | Initiates | Overweight | $220 | $122.09 | $121.56 | -0.4% | +3.0% | -4.1% | -1.3% | -4.0% | -8.0% |
| Mar 31 | Chardan Capital | Maintains | Buy → Buy | — | $110.66 | $115.58 | +4.4% | +12.6% | -3.4% | +2.6% | -2.9% | +0.1% |
| Mar 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $117.04 | $115.00 | -1.7% | -0.7% | +3.6% | -2.3% | -4.5% | -1.5% |
| Mar 16 | Chardan Capital | Maintains | Buy → Buy | — | $122.06 | $124.08 | +1.7% | +3.3% | -4.2% | -5.4% | -0.3% | -1.2% |
| Feb 25 | BTIG | Maintains | Buy → Buy | — | $120.41 | $122.71 | +1.9% | +6.8% | +15.3% | -9.0% | -1.8% | -0.8% |
| Feb 25 | Mizuho | Maintains | Outperform → Outperform | — | $120.41 | $122.71 | +1.9% | +6.8% | +15.3% | -9.0% | -1.8% | -0.8% |
| Feb 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $87.84 | $113.00 | +28.6% | +37.1% | +6.8% | +15.3% | -9.0% | -1.8% |
| Feb 24 | Chardan Capital | Maintains | Buy → Buy | — | $87.84 | $113.00 | +28.6% | +37.1% | +6.8% | +15.3% | -9.0% | -1.8% |
| Jan 29 | BTIG | Maintains | Buy → Buy | — | $78.71 | $78.20 | -0.6% | +4.1% | -6.4% | +4.2% | +0.0% | +2.6% |
| Jan 16 | BTIG | Maintains | Buy → Buy | — | $103.98 | $104.14 | +0.2% | -4.1% | -1.7% | -4.2% | -2.0% | -7.4% |
| Dec 16 | Truist | Maintains | Buy → Buy | — | $88.98 | $90.01 | +1.2% | +8.8% | -5.0% | +4.6% | +3.6% | +9.4% |
| Dec 16 | TD Cowen | Maintains | Buy → Buy | — | $88.98 | $90.01 | +1.2% | +8.8% | -5.0% | +4.6% | +3.6% | +9.4% |
| Dec 16 | Chardan Capital | Maintains | Buy → Buy | — | $88.98 | $90.01 | +1.2% | +8.8% | -5.0% | +4.6% | +3.6% | +9.4% |
| Dec 16 | Canaccord Genuity | Maintains | Buy → Buy | — | $88.98 | $90.01 | +1.2% | +8.8% | -5.0% | +4.6% | +3.6% | +9.4% |
| Dec 15 | BTIG | Maintains | Buy → Buy | — | $98.58 | $109.66 | +11.2% | -9.7% | +8.8% | -5.0% | +4.6% | +3.6% |
| Dec 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $98.58 | $109.66 | +11.2% | -9.7% | +8.8% | -5.0% | +4.6% | +3.6% |
| Nov 24 | Stifel | Maintains | Buy → Buy | — | $94.09 | $96.00 | +2.0% | +4.2% | -3.2% | +5.4% | +2.8% | -8.0% |
| Nov 19 | Raymond James | Upgrade | Outperform → Strong Buy | — | $82.94 | $87.94 | +6.0% | +16.8% | -5.5% | +2.8% | +4.2% | -3.2% |
| Nov 13 | Chardan Capital | Maintains | Buy → Buy | — | $81.54 | $83.13 | +1.9% | -1.3% | +4.0% | -2.5% | +1.6% | +16.8% |
| Nov 13 | Canaccord Genuity | Maintains | Buy → Buy | — | $81.54 | $83.13 | +1.9% | -1.3% | +4.0% | -2.5% | +1.6% | +16.8% |
| Nov 10 | Truist | Maintains | Buy → Buy | — | $77.83 | $80.00 | +2.8% | +3.2% | -3.0% | +4.7% | -1.3% | +4.0% |
| Nov 7 | Chardan Capital | Maintains | Buy → Buy | — | $78.63 | $79.78 | +1.5% | -1.0% | +3.2% | -3.0% | +4.7% | -1.3% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $75.75 | $78.36 | +3.4% | +3.8% | -1.0% | +3.2% | -3.0% | +4.7% |
| Nov 6 | TD Cowen | Maintains | Buy → Buy | — | $75.75 | $78.36 | +3.4% | +3.8% | -1.0% | +3.2% | -3.0% | +4.7% |
| Nov 6 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $75.75 | $78.36 | +3.4% | +3.8% | -1.0% | +3.2% | -3.0% | +4.7% |
| Oct 9 | Canaccord Genuity | Maintains | Buy → Buy | — | $74.85 | $76.43 | +2.1% | -6.4% | -0.3% | +9.0% | -3.5% | +3.8% |
| Oct 2 | Truist | Maintains | Buy → Buy | — | $63.23 | $64.36 | +1.8% | -0.9% | +5.0% | +3.3% | +4.1% | +5.8% |
| Sep 26 | Chardan Capital | Maintains | Buy → Buy | — | $57.69 | $58.79 | +1.9% | +3.3% | +4.5% | +0.7% | +0.9% | -0.9% |
| Sep 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $58.87 | $60.03 | +2.0% | -2.0% | +3.3% | +4.5% | +0.7% | +0.9% |
| Sep 24 | Stifel | Maintains | Buy → Buy | — | $56.69 | $57.06 | +0.7% | +3.8% | -2.0% | +3.3% | +4.5% | +0.7% |
| Aug 19 | Canaccord Genuity | Maintains | Buy → Buy | — | $49.55 | $49.75 | +0.4% | -2.1% | +4.0% | +1.7% | +4.1% | -6.2% |
| Aug 15 | Chardan Capital | Maintains | Buy → Buy | — | $46.10 | $47.12 | +2.2% | +2.6% | +4.8% | -2.1% | +4.0% | +1.7% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $46.10 | $47.12 | +2.2% | +2.6% | +4.8% | -2.1% | +4.0% | +1.7% |
| May 16 | Canaccord Genuity | Maintains | Buy → Buy | — | $21.61 | $21.80 | +0.9% | +2.0% | +2.3% | +3.0% | -1.0% | -3.9% |
| Apr 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.44 | $22.94 | -2.1% | +3.6% | -0.8% | +1.5% | -2.5% | -3.9% |
| Apr 2 | Canaccord Genuity | Maintains | Buy → Buy | — | $23.59 | $24.12 | +2.2% | +14.3% | -9.4% | -1.8% | -16.3% | +2.2% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.99 | $28.30 | +1.1% | -15.7% | +14.3% | -9.4% | -1.8% | -16.3% |
| Feb 26 | Canaccord Genuity | Maintains | Buy → Buy | — | $19.31 | $19.30 | -0.1% | -2.6% | +0.3% | +2.8% | +0.9% | +5.9% |
| Feb 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.72 | $15.85 | +0.8% | +2.7% | +4.5% | +18.5% | -2.2% | +7.4% |
| Jan 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.25 | $13.89 | -2.5% | -2.0% | -6.9% | -0.2% | +2.5% | -0.6% |
| Jan 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.00 | $11.89 | -0.9% | +10.4% | +11.4% | -0.2% | -3.3% | -2.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jul 15, 2026 | Goin KathleenOff | Chief Operating Officer | Sell | 1,911 | $150.25 | $287K | — | -21.04% | -3.63% |
| Jul 15, 2026 | Goin KathleenOff | Chief Operating Officer | Sell | 1,029 | $149.27 | $154K | 1,911 | -21.04% | -3.63% |
| Jul 15, 2026 | Goin KathleenOff | Chief Operating Officer | Sell | 840 | $148.40 | $125K | 2,940 | -21.04% | -3.63% |
| Jul 15, 2026 | Goin KathleenOff | Chief Operating Officer | Sell | 522 | $147.14 | $77K | 3,780 | -21.04% | -3.63% |
| Jun 17, 2026 | Goin KathleenOff | Chief Operating Officer | Sell | 25 | $112.23 | $3K | — | -0.13% | +4.47% |
| Jun 17, 2026 | Goin KathleenOff | Chief Operating Officer | Sell | 1,887 | $111.31 | $210K | 25 | -0.13% | +4.47% |
| Jun 17, 2026 | Goin KathleenOff | Chief Operating Officer | Sell | 2,390 | $110.26 | $264K | 1,912 | -0.13% | +4.47% |
8-K · 2.02
!! High
Palvella Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Aug 4
8-K · 5.02
!!! Very High
Palvella Therapeutics, Inc. -- 8-K 5.02: Executive Change
Jun 30
8-K · 5.02
!!! Very High
Palvella Therapeutics, Inc. -- 8-K 5.02: Executive Change
Jun 16
8-K · 8.01
!! High
Palvella Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
May 20
8-K · 8.01
!! High
Palvella Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
May 15
8-K · 8.01
!! High
Palvella Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
May 13
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
A dermatology-experienced board member joining PVLA could strengthen its biotech credibility and clinical development capabilities, particularly valuable if the company focuses on skin disease treatments.
Apr 13
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
PVLA's forward-looking statements carry significant execution risk, suggesting management is cautious about near-term outcomes and investors should be skeptical of optimistic guidance.
Apr 7
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Palvella disclosed earnings results and presentation materials via press release and earnings call on March 31, 2026, likely affecting stock price based on operational performance metrics investors should evaluate.
Mar 31
8-K · 1.01
! Medium
Palvella Therapeutics, Inc. -- 8-K 1.01: Underwriting / Securities
Palvella Therapeutics completed a public offering of 1.6 million shares at $125 per share, raising approximately $200 million with underwriter option for additional shares.
Feb 26
8-K · 7.01
! Medium
Palvella Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Palvella Therapeutics will present Phase 3 SELVA topline results for QTORIN gel treating microcystic lymphatic malformations, potentially advancing its pipeline and supporting future regulatory approval.
Feb 24
8-K
Palvella Therapeutics, Inc. -- 8-K Filing
Palvella Therapeutics disclosed financial results for the year ended December 31, 2025, providing investors updated information on the company's financial position and operational performance.
Feb 24
8-K · 8.01
!! High
Palvella Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Palvella Therapeutics filed a material event announcement via press release, though the specific details require reviewing the attached exhibit to understand the announcement's impact on shareholders.
Feb 24
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 477,294 | $59M | New | Mar 2026 |
| 2 | Morgan Stanley | 441,324 | $46M | Added | Dec 2025 |
| 3 | Woodline Partners Lp | 317,517 | $40M | Added | Mar 2026 |
| 4 | Fmr Llc | 215,808 | $27M | Reduced | Mar 2026 |
| 5 | Mpm Bioimpact Llc | 206,404 | $26M | — | Mar 2026 |
| 6 | Primecap Management Co/ca/ | 195,030 | $24M | New | Mar 2026 |
| 7 | Artisan Partners Limited Partnership | 193,796 | $24M | Reduced | Mar 2026 |
| 8 | Alyeska Investment Group, L.p. | 179,922 | $22M | New | Mar 2026 |
| 9 | Ubs Group Ag | 104,537 | $13M | Added | Mar 2026 |
| 10 | Millennium Management | 93,646 | $12M | Added | Mar 2026 |
| 11 | Vanguard Portfolio Management Llc | 90,858 | $11M | New | Mar 2026 |
| 12 | Point72 Asset Management | 88,160 | $11M | Added | Mar 2026 |
| 13 | Samsara Biocapital, Llc | 104,817 | $11M | Reduced | Dec 2025 |
| 14 | Avidity Partners Management Lp | 70,000 | $9M | New | Mar 2026 |
| 15 | Northern Trust Corp | 64,371 | $8M | Added | Mar 2026 |
| 16 | Clearbridge Investments, Llc | 59,410 | $7M | Reduced | Mar 2026 |
| 17 | Neuberger Berman Group Llc | 49,103 | $6M | Added | Mar 2026 |
| 18 | Invesco Ltd. | 48,527 | $6M | Reduced | Mar 2026 |
| 19 | Ensign Peak Advisors, Inc | 39,223 | $5M | New | Mar 2026 |
| 20 | Bank Of America Corp /de/ | 37,972 | $5M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$2.24B
Enterprise Value
$1.69B
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.54x
P/B
62.71x
P/S
—
P/FCF
-69.77x
EV/EBITDA
—
Shares Out
11.3M
Financials (TTM)
Revenue
$0
Net Income
-$61.7M
EBITDA
-$50.0M
Free Cash Flow
-$25.0M
Op Cash Flow
-$25.0M
EPS Basic
$-3.71
EPS Diluted
$-4.83
EPS Forward
$-5.16
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$59.6M
Total Liab.
$31.6M
Total Equity
$28.0M
Cash
$58.0M
LT Debt
$431K
Book Value/Sh
$2.49
Debt/Equity
0.02x
Current Ratio
5.20
Quick Ratio
5.20
Returns & Growth
ROE
-149.1%
ROA
-70.0%
ROIC
-79.7%
Rev Growth YoY
+0.0%
EPS Growth YoY
+52.6%
Price Returns
2W
+8.7%
1M
+7.1%
3M
+23.3%
6M
+89.1%
12M
+258.9%
Technicals
52W High
$161.38
52W Low
$41.71
50d MA
$135.54
200d MA
$112.64
RSI (14)
60.60
ATR (14)
$8.12
Beta
-0.20
Avg Volume
215K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$203.92
High
$255.00
Low
$143.00
Median
$204.50
Data updated apr 26, 2026 9:18pm
· Source: financialmodelingprep.com